Forkhead Box P3 Methylation and Expression in Men with Obstructive Sleep Apnea.
FOXP3 expression
FOXP3 methylation
epigenetics.
obstructive sleep apnea
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Mar 2020
23 Mar 2020
Historique:
received:
22
01
2020
revised:
17
03
2020
accepted:
19
03
2020
entrez:
27
3
2020
pubmed:
27
3
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Epigenetic changes in obstructive sleep apnea (OSA) have been proposed as a mechanism for end-organ vulnerability. In children with OSA, Forkhead Box P3 (FOXP3) DNA methylation were associated with inflammatory biomarkers; however, the methylation pattern and its effect in the expression of this gene have not been tested in adults with OSA. Plasma samples from subjects without comorbid conditions other than OSA were analyzed (the Epigenetics Status and Subclinical Atherosclerosis in Obstructive Sleep Apnea (EPIOSA) Study: NCT02131610). In 16 patients with severe OSA (Apnea-Hypopnea Index-AHI- > 30 events/h) and seven matched controls (AHI < 5), methylation of FOXP3 gen was evaluated by PCR of the promoter and by pyrosequencing of the intron 1 Treg-specific demethylated region (TSDR). In another 74 patients with OSA (AHI > 10) and 31 controls, we quantified FOXP3 protein expression by ELISA and gene expression by quantitative real-time PCR. C-reactive protein (CRP) and plasma Treg cells were also evaluated. Neither the levels of the promoter nor the TSDR demethylated region were different between controls and patients with OSA, whether they were grouped by normal or high CRP. FOXP3 protein and mRNA expression did not differ between groups. FOXP3 methylation or its expression is not altered in adults with OSA, whatever their inflammatory status.
Sections du résumé
BACKGROUND
BACKGROUND
Epigenetic changes in obstructive sleep apnea (OSA) have been proposed as a mechanism for end-organ vulnerability. In children with OSA, Forkhead Box P3 (FOXP3) DNA methylation were associated with inflammatory biomarkers; however, the methylation pattern and its effect in the expression of this gene have not been tested in adults with OSA.
METHODS
METHODS
Plasma samples from subjects without comorbid conditions other than OSA were analyzed (the Epigenetics Status and Subclinical Atherosclerosis in Obstructive Sleep Apnea (EPIOSA) Study: NCT02131610). In 16 patients with severe OSA (Apnea-Hypopnea Index-AHI- > 30 events/h) and seven matched controls (AHI < 5), methylation of FOXP3 gen was evaluated by PCR of the promoter and by pyrosequencing of the intron 1 Treg-specific demethylated region (TSDR). In another 74 patients with OSA (AHI > 10) and 31 controls, we quantified FOXP3 protein expression by ELISA and gene expression by quantitative real-time PCR. C-reactive protein (CRP) and plasma Treg cells were also evaluated.
RESULTS
RESULTS
Neither the levels of the promoter nor the TSDR demethylated region were different between controls and patients with OSA, whether they were grouped by normal or high CRP. FOXP3 protein and mRNA expression did not differ between groups.
CONCLUSIONS
CONCLUSIONS
FOXP3 methylation or its expression is not altered in adults with OSA, whatever their inflammatory status.
Identifiants
pubmed: 32210181
pii: ijms21062233
doi: 10.3390/ijms21062233
pmc: PMC7139835
pii:
doi:
Substances chimiques
Biomarkers
0
FOXP3 protein, human
0
Forkhead Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : FIS PI12/01275
Organisme : Sociedad Española de Neumología y Cirugía Torácica
ID : 071/2012
Organisme : Aragon Society of Pneumology
ID : 02/2013
Organisme : Gobierno de Aragón/Fondo Social Europeo "Construyendo Europa desde Aragón"
ID : LAGENBIO A19-17R
Références
Wiley Interdiscip Rev Syst Biol Med. 2010 May-Jun;2(3):336-361
pubmed: 20836033
Rev Esp Cardiol. 2010 Jan;63(1):97-102
pubmed: 20089231
J Intern Med. 2007 May;261(5):488-99
pubmed: 17444888
Lancet. 2005 Mar 19-25;365(9464):1046-53
pubmed: 15781100
J Clin Sleep Med. 2012 Oct 15;8(5):597-619
pubmed: 23066376
Neurobiol Aging. 2019 Feb;74:213-224
pubmed: 30497015
J Allergy Clin Immunol. 2013 Feb;131(2):592-4.e1-3
pubmed: 23260754
Sleep. 2013 Jun 01;36(6):913-22
pubmed: 23729935
J Clin Sleep Med. 2017 Mar 15;13(3):479-504
pubmed: 28162150
Am J Respir Crit Care Med. 2012 Feb 1;185(3):330-8
pubmed: 22077067
Sleep. 2019 Oct 21;42(11):
pubmed: 31418028
J Clin Invest. 2013 Mar;123(3):1323-34
pubmed: 23426179
J Allergy Clin Immunol. 2014 Feb;133(2):500-10
pubmed: 24636474
J Allergy Clin Immunol. 2010 Oct;126(4):845-852.e10
pubmed: 20920773
JAMA. 2004 Apr 28;291(16):2013-6
pubmed: 15113821
Mediators Inflamm. 2012;2012:815308
pubmed: 23345934
Am Heart J. 2010 Jul;160(1):49-57.e1
pubmed: 20598972
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9327-32
pubmed: 27457926
Clin Transl Allergy. 2015 Oct 20;5:35
pubmed: 26500760
Mult Scler. 2018 Jan;24(1):22-31
pubmed: 29307297
Sleep. 2016 Apr 01;39(4):743-55
pubmed: 26888452
Circulation. 2003 Mar 4;107(8):1129-34
pubmed: 12615790
Br J Dermatol. 2014 Jul;171(1):39-47
pubmed: 24641670
Am J Respir Crit Care Med. 2002 May 1;165(9):1217-39
pubmed: 11991871
BMC Pulm Med. 2014 Jul 12;14:114
pubmed: 25016368
Circulation. 2010 Jul 27;122(4):352-60
pubmed: 20625114
Otolaryngol Head Neck Surg. 2010 Jul;143(1):72-7
pubmed: 20620622
Epigenetics. 2010 May 16;5(4):293-6
pubmed: 20418669
Endocr Rev. 2011 Apr;32(2):159-224
pubmed: 20971919
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):E2784-93
pubmed: 22988108
Atherosclerosis. 2008 Jul;199(1):3-11
pubmed: 18378239